Physician profile
Peter S Stack
NPI 1275649725
$2,373.59
in general payments reported to CMS, 2019-2025
24 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $247 · 2021: $318 · 2022: $103 · 2023: $366 · 2024: $581 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.66 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $382.27 | 2019-2025 | Otezla, Repatha, Repatha |
| Eisai INC. | $213.76 | 2020-2025 | |
| Pfizer INC. | $174.28 | 2019-2025 | |
| Novo Nordisk INC | $167.61 | 2019-2025 | Wegovy |
| Exact Sciences Corporation | $166.16 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $127.89 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $84.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $80.92 | 2024-2025 | |
| Astellas Pharma US INC | $76.77 | 2024-2025 | Veozah |
| Lilly USA, LLC | $67.33 | 2024 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.41 | 2023-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $50.38 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $49.18 | 2020-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $45.65 | 2021-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.06 | 2021-2023 | Zerbaxa, Dificid |
| Amarin Pharma, INC. | $29.98 | 2019 | |
| Dynavax Technologies Corporation | $29.29 | 2022-2024 | Heplisav-B |
| Medivance, INC. | $27.23 | 2020 | |
| Dexcom, INC. | $20.73 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $18.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.55 | 2025 | |
| Cleerly, INC. | $13.48 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Arbor Pharmaceuticals, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.